Cargando…
Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
Aims: Few studies have compared the association between dosing of spironolactone and outcomes in patients with heart failure with preserved ejection fraction (HFpEF), and whether spironolactone dose could significantly affect the prognosis of HFpEF patients combined with chronic kidney disease (CKD)...
Autores principales: | Li, Jun-Feng, Qu, Xiang, Gao, Zhan, Chen, Chang-Xi, Zhang, Feng-Yu, Cheng, Ling, Zhou, Xi, Zhou, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911545/ https://www.ncbi.nlm.nih.gov/pubmed/36778020 http://dx.doi.org/10.3389/fphar.2023.1084442 |
Ejemplares similares
-
Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022) -
Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022) -
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019) -
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020) -
A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
por: Belkin, Mark N., et al.
Publicado: (2021)